Compare DexCom, Inc. (DXCM) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $74.51, down 5.85% in the last session amid broad bearish technical signals. The fund provides exposure to 38 global rare earth and strategic metals companies, heavily weighted toward China, with annualized volatility around 50% (Seeking Alpha, 2026-07-14). Recent news highlights rare earths' strategic importance amid China's export controls and reshoring trends, though financial ratios are not disclosed for this ETF structure.

Outlook remains tied to geopolitical supply dynamics and commodity cycles, offering growth potential but with high risk due to concentration and volatility. Key risks include China dependency, regulatory shifts, and market churn, making it suitable only for aggressive portfolios as a satellite holding.